A detailed history of Ubs Asset Management Americas Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 140,998 shares of ETNB stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,998
Previous 139,374 1.17%
Holding current value
$1.11 Million
Previous $1.12 Million 6.54%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $11,952 - $15,687
1,624 Added 1.17%
140,998 $1.04 Million
Q2 2024

Aug 13, 2024

BUY
$7.31 - $10.9 $487,386 - $726,746
66,674 Added 91.71%
139,374 $1.12 Million
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $110,568 - $187,272
13,600 Added 23.01%
72,700 $846,000
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $42,697 - $102,768
6,411 Added 12.17%
59,100 $660,000
Q3 2023

Nov 13, 2023

BUY
$15.06 - $19.41 $793,496 - $1.02 Million
52,689 New
52,689 $813,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $366M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.